CR2Cancer

Summary
Symbol	YY1
Name	YY1 transcription factor
Aliases	UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Location	14q32.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Domain, Function and Classification > Gene Ontology > KEGG and Reactome Pathway

> Domain, Function and Classification

[ TOP ]

Domain

Function

Multifunctional transcription factor that exhibits positive and negative control on a large number of cellular and viral genes by binding to sites overlapping the transcription start site. Binds to the consensus sequence 5'-CCGCCATNTT-3'; some genes have been shown to contain a longer binding motif allowing enhanced binding; the initial CG dinucleotide can be methylated greatly reducing the binding affinity. The effect on transcription regulation is depending upon the context in which it binds and diverse mechanisms of action include direct activation or repression, indirect activation or repression via cofactor recruitment, or activation or repression by disruption of binding sites or conformational DNA changes. Its activity is regulated by transcription factors and cytoplasmic proteins that have been shown to abrogate or completely inhibit YY1-mediated activation or repression. For example, it acts as a repressor in absence of adenovirus E1A protein but as an activator in its presence. Acts synergistically with the SMAD1 and SMAD4 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression (PubMed:15329343). Binds to SMAD binding elements (SBEs) (5'-GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions. May play an important role in development and differentiation. Proposed to recruit the PRC2/EED-EZH2 complex to target genes that are transcriptional repressed. Involved in DNA repair. In vitro, binds to DNA recombination intermediate structures (Holliday junctions). ; FUNCTION: Proposed core component of the chromatin remodeling INO80 complex which is involved in transcriptional regulation, DNA replication and probably DNA repair; proposed to target the INO80 complex to YY1-responsive elements.

Classification

Class	Modification	Substrate	Product	PubMed
Chromatin remodelling cofactor	#	DNA motif	#	11445535

> Gene Ontology [ TOP ]
Biological Process	GO:0000724 double-strand break repair via homologous recombination GO:0000725 recombinational repair GO:0001654 eye development GO:0003002 regionalization GO:0006302 double-strand break repair GO:0006310 DNA recombination GO:0006403 RNA localization GO:0007283 spermatogenesis GO:0007389 pattern specification process GO:0007423 sensory organ development GO:0009314 response to radiation GO:0009411 response to UV GO:0009416 response to light stimulus GO:0009952 anterior/posterior pattern specification GO:0010225 response to UV-C GO:0034644 cellular response to UV GO:0034694 response to prostaglandin GO:0034696 response to prostaglandin F GO:0043010 camera-type eye development GO:0048232 male gamete generation GO:0048592 eye morphogenesis GO:0048593 camera-type eye morphogenesis GO:0070555 response to interleukin-1 GO:0071214 cellular response to abiotic stimulus GO:0071347 cellular response to interleukin-1 GO:0071478 cellular response to radiation GO:0071482 cellular response to light stimulus GO:0090596 sensory organ morphogenesis
Molecular Function	GO:0000217 DNA secondary structure binding GO:0000400 four-way junction DNA binding GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001078 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001158 enhancer sequence-specific DNA binding GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0003713 transcription coactivator activity GO:0003714 transcription corepressor activity GO:0035326 enhancer binding GO:0042826 histone deacetylase binding GO:0043566 structure-specific DNA binding GO:0046332 SMAD binding
Cellular Component	GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0005667 transcription factor complex GO:0016363 nuclear matrix GO:0031011 Ino80 complex GO:0031519 PcG protein complex GO:0033202 DNA helicase complex GO:0034399 nuclear periphery GO:0044454 nuclear chromosome part GO:0070603 SWI/SNF superfamily-type complex GO:0097346 INO80-type complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-5619507: Activation of HOX genes during differentiation R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis R-HSA-5696394: DNA Damage Recognition in GG-NER R-HSA-73894: DNA Repair R-HSA-5688426: Deubiquitination R-HSA-1266738: Developmental Biology R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-5696399: Global Genome Nucleotide Excision Repair (GG-NER) R-HSA-392499: Metabolism of proteins R-HSA-5696398: Nucleotide Excision Repair R-HSA-597592: Post-translational protein modification R-HSA-8866910: TFAP2 (AP-2) family regulates transcription of growth factors and their receptors R-HSA-8864260: Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors R-HSA-5689603: UCH proteinases

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-5619507: Activation of HOX genes during differentiation
R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-5696394: DNA Damage Recognition in GG-NER
R-HSA-73894: DNA Repair
R-HSA-5688426: Deubiquitination
R-HSA-1266738: Developmental Biology
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-5696399: Global Genome Nucleotide Excision Repair (GG-NER)
R-HSA-392499: Metabolism of proteins
R-HSA-5696398: Nucleotide Excision Repair
R-HSA-597592: Post-translational protein modification
R-HSA-8866910: TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
R-HSA-8864260: Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors
R-HSA-5689603: UCH proteinases

Summary
Symbol	YY1
Name	YY1 transcription factor
Aliases	UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Location	14q32.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Mutation landscape in primary tumor tissue from TCGA > Mutation landscape in cancer cell line from CCLE > All mutations from COSMIC database V81 > Variations from text mining

> The Cancer Genome Atlas (TCGA) [ TOP ]

> Cancer Cell Line Encyclopedia (CCLE) [ TOP ]
There is no record.

> Catalogue of Somatic Mutations in Cancer (COSMIC)

[ TOP ]

COSMIC ID	CDS change	AA change	Mutation Type	Anatomical Site
COSM4049062	c.740C>T	p.S247L	Substitution - Missense	Stomach
COSM5134498	c.682_683insA	p.D231fs*3	Insertion - Frameshift	Large_intestine
COSM5015261	c.394C>A	p.L132I	Substitution - Missense	Kidney
COSM1128336	c.759A>G	p.E253E	Substitution - coding silent	Haematopoietic_and_lymphoid_tissue
COSM4826375	c.705G>C	p.E235D	Substitution - Missense	Cervix
COSM6001453	c.745C>T	p.P249S	Substitution - Missense	Prostate
COSM551917	c.1154G>T	p.C385F	Substitution - Missense	Skin
COSM5714871	c.1219C>T	p.H407Y	Substitution - Missense	Haematopoietic_and_lymphoid_tissue
COSM5987614	c.985G>C	p.E329Q	Substitution - Missense	Salivary_gland
COSM3493763	c.785C>T	p.P262L	Substitution - Missense	Skin
COSM1128336	c.759A>G	p.E253E	Substitution - coding silent	Breast
COSM3726820	c.682delG	p.E228fs*28	Deletion - Frameshift	Lung
COSM5770868	c.394C>T	p.L132F	Substitution - Missense	Breast
COSM4413592	c.1106A>G	p.N369S	Substitution - Missense	Genital_tract
COSM5643108	c.21C>G	p.L7L	Substitution - coding silent	Oesophagus
COSM217058	c.1225A>G	p.K409E	Substitution - Missense	Liver
COSM6001453	c.745C>T	p.P249S	Substitution - Missense	Prostate
COSM248397	c.127_129delGAG	p.E43delE	Deletion - In frame	Prostate
COSM4147812	c.755C>T	p.S252L	Substitution - Missense	Thyroid
COSM5824322	c.240C>A	p.H80Q	Substitution - Missense	Liver
COSM5779515	c.1205C>A	p.S402Y	Substitution - Missense	Breast
COSM2261797	c.683delA	p.D231fs*25	Deletion - Frameshift	Stomach
COSM4607589	c.830C>A	p.A277E	Substitution - Missense	Adrenal_gland
COSM2261793	c.422G>A	p.G141D	Substitution - Missense	Large_intestine
COSM5350163	c.728T>C	p.I243T	Substitution - Missense	Lung
COSM2261793	c.422G>A	p.G141D	Substitution - Missense	Large_intestine
COSM1128336	c.759A>G	p.E253E	Substitution - coding silent	Prostate
COSM1607322	c.206_207insCCA	p.H80_P81insH	Insertion - In frame	Liver
COSM1128336	c.759A>G	p.E253E	Substitution - coding silent	Lung
COSM4935859	c.264G>T	p.P88P	Substitution - coding silent	Liver
COSM459230	c.381C>T	p.F127F	Substitution - coding silent	Cervix
COSM4049064	c.806A>G	p.D269G	Substitution - Missense	Stomach
COSM5573755	c.489_490insTCG	p.S167_G168insS	Insertion - In frame	Prostate
COSM1607322	c.206_207insCCA	p.H80_P81insH	Insertion - In frame	Upper_aerodigestive_tract
COSM4147813	c.756A>C	p.S252S	Substitution - coding silent	Thyroid
COSM2261793	c.422G>A	p.G141D	Substitution - Missense	Stomach
COSM1128336	c.759A>G	p.E253E	Substitution - coding silent	Prostate
COSM3746340	c.225T>C	p.H75H	Substitution - coding silent	Liver
COSM3814233	c.869A>G	p.D290G	Substitution - Missense	Breast
COSM2261806	c.1135G>A	p.G379R	Substitution - Missense	Stomach
COSM4147814	c.757G>T	p.E253*	Substitution - Nonsense	Thyroid
COSM5705618	c.898C>T	p.H300Y	Substitution - Missense	Haematopoietic_and_lymphoid_tissue
COSM2261783	c.72C>T	p.H24H	Substitution - coding silent	Kidney
COSM949287	c.207_209delCCA	p.H80delH	Deletion - In frame	Endometrium
COSM2261783	c.72C>T	p.H24H	Substitution - coding silent	Kidney
COSM242295	c.367G>A	p.A123T	Substitution - Missense	Prostate
COSM3401114	c.223C>G	p.H75D	Substitution - Missense	Central_nervous_system
COSM217058	c.1225A>G	p.K409E	Substitution - Missense	Liver
COSM949289	c.802A>G	p.I268V	Substitution - Missense	Endometrium
COSM140049	c.1082G>A	p.G361E	Substitution - Missense	Skin
COSM551917	c.1154G>T	p.C385F	Substitution - Missense	Central_nervous_system
COSM4458558	c.108C>T	p.I36I	Substitution - coding silent	Skin
COSM5681224	c.450G>T	p.L150L	Substitution - coding silent	Soft_tissue
COSM5510710	c.144C>G	p.D48E	Substitution - Missense	Biliary_tract
COSM5635088	c.239A>C	p.H80P	Substitution - Missense	Oesophagus
COSM6001452	c.54C>T	p.A18A	Substitution - coding silent	Prostate
COSM5937643	c.762T>A	p.Y254*	Substitution - Nonsense	Skin
COSM5217186	c.1134C>T	p.T378T	Substitution - coding silent	Biliary_tract
COSM1637539	c.1069T>C	p.F357L	Substitution - Missense	Bone
COSM4741927	c.13G>A	p.D5N	Substitution - Missense	Large_intestine
COSM4887714	c.337G>T	p.V113L	Substitution - Missense	Upper_aerodigestive_tract
COSM949288	c.283_284delAC	p.T95fs*52	Deletion - Frameshift	Endometrium
COSM1128336	c.759A>G	p.E253E	Substitution - coding silent	Breast
COSM4413592	c.1106A>G	p.N369S	Substitution - Missense	Genital_tract
COSM217058	c.1225A>G	p.K409E	Substitution - Missense	Liver
COSM3706114	c.228C>T	p.H76H	Substitution - coding silent	Liver
COSM3814234	c.1032A>C	p.Q344H	Substitution - Missense	Breast
COSM5819740	c.56A>C	p.E19A	Substitution - Missense	Liver
COSM4387152	c.757G>A	p.E253K	Substitution - Missense	Lung
COSM1233068	c.1124G>A	p.R375Q	Substitution - Missense	Haematopoietic_and_lymphoid_tissue
COSM357838	c.528C>T	p.G176G	Substitution - coding silent	Lung
COSM3746340	c.225T>C	p.H75H	Substitution - coding silent	Prostate
COSM5913637	c.878C>T	p.P293L	Substitution - Missense	Skin
COSM4938936	c.921C>G	p.F307L	Substitution - Missense	Liver
COSM4147811	c.313C>A	p.L105M	Substitution - Missense	Thyroid
COSM4049063	c.783T>C	p.P261P	Substitution - coding silent	Stomach
COSM6001453	c.745C>T	p.P249S	Substitution - Missense	Prostate
COSM248397	c.127_129delGAG	p.E43delE	Deletion - In frame	Large_intestine
COSM5419956	c.176_177insCGG	p.G64_H65insG	Insertion - In frame	Pancreas
COSM4150715	c.117A>G	p.T39T	Substitution - coding silent	Kidney
COSM4413592	c.1106A>G	p.N369S	Substitution - Missense	Central_nervous_system
COSM3936404	c.498G>T	p.S166S	Substitution - coding silent	Oesophagus
COSM6001453	c.745C>T	p.P249S	Substitution - Missense	Prostate
COSM5037485	c.345C>T	p.G115G	Substitution - coding silent	Large_intestine
COSM1717684	c.1115C>G	p.T372R	Substitution - Missense	Adrenal_gland
COSM4431627	c.111G>C	p.E37D	Substitution - Missense	Oesophagus
COSM4741928	c.1128C>T	p.I376I	Substitution - coding silent	Large_intestine
COSM4388357	c.1103T>A	p.F368Y	Substitution - Missense	Pancreas
COSM949287	c.207_209delCCA	p.H80delH	Deletion - In frame	Endometrium
COSM3706114	c.228C>T	p.H76H	Substitution - coding silent	Liver
COSM1233068	c.1124G>A	p.R375Q	Substitution - Missense	Large_intestine
COSM4150715	c.117A>G	p.T39T	Substitution - coding silent	Kidney

> Text Mining based Variations

[ TOP ]

PMID	Variation	Cancer	Evidence
28505004	Mutation	Plasma Cell Myeloma	A gene fusion involving EWSR1 and YY1 gene on 14q32 has been reported in 2 patients over the age of 60 with peritoneal MM.
25787250	Mutation	Pancreatic Insulinoma	Exome and targeted sequencing revealed that 14 of 43 insulinomas harbored the identical somatic mutation in the DNA-binding zinc finger of the transcription factor Yin Yang 1 (YY1). These findings indicate that YY1(T372R) mutations are neomorphic, resulting in constitutive activation of cAMP and Ca(2+) signaling pathways involved in insulin secretion.
25763608	Mutation	Pancreatic Insulinoma	The somatic Thr372Arg YY1 mutation is a relevant finding in female patients with sporadic insulinomas.
23630070	Mutation	Mesothelioma	Screening 15 additional cases of mesothelioma from which we had RNA but no cytogenetic information, we identified one more tumor carrying an EWSR1-YY1 fusion gene but not the reciprocal YY1-EWSR1 transcript

Summary
Symbol	YY1
Name	YY1 transcription factor
Aliases	UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Location	14q32.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Post-translational modification (PTM)

> Post-translational modification (PTM)

[ TOP ]

Filter By:

Uniprot ID	Position	Amino Acid	Description	Upstream Enzyme	Affected By Mutation	Amino Acid Sequence Variant
P25490	187	S	Phosphoserine	-	No	None detected
P25490	247	S	Phosphoserine	-	Yes	p.S247* (cancer: BLCA); p.S247L (cancer: STAD)
P25490	378	T	Phosphothreonine	-	No	None detected

Summary
Symbol	YY1
Name	YY1 transcription factor
Aliases	UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Location	14q32.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Expression analysis in primary tumor tissue from TCGA > Expression level in cancer cell line from CCLE > Expression level in human normal tissue from HPA > Text mining based expression change

> The Cancer Genome Atlas (TCGA)

[ TOP ]

Differential expression analysis for cancers with more than 10 normal samples

Cancer	Full Name	# N	# T	Median (N)	Median (T)	LogFC	Adj. P	Status
BLCA	Bladder urothelial carcinoma	19	408	5.57	5.968	0.395	0.000593	NS
BRCA	Breast invasive carcinoma	112	1100	5.934	6.187	0.262	3.54e-10	NS
CESC	Cervical and endocervical cancers	3	306	5.604	6.228	NA	NA	NA
COAD	Colon adenocarcinoma	41	459	6.004	6.116	0.109	0.057	NS
ESCA	Esophageal carcinoma	11	185	6.118	6.528	0.425	0.00243	NS
GBM	Glioblastoma multiforme	5	166	5.254	5.621	NA	NA	NA
HNSC	Head and Neck squamous cell carcinoma	44	522	5.644	6.018	0.381	1.47e-07	NS
KIRC	Kidney renal clear cell carcinoma	72	534	5.931	5.893	-0.062	0.151	NS
KIRP	Kidney renal papillary cell carcinoma	32	291	5.693	5.461	-0.226	0.00766	NS
LAML	Acute Myeloid Leukemia	0	173	NA	6.629	NA	NA	NA
LGG	Brain Lower Grade Glioma	0	530	NA	5.365	NA	NA	NA
LIHC	Liver hepatocellular carcinoma	50	373	5.306	5.147	-0.187	0.00868	NS
LUAD	Lung adenocarcinoma	59	517	5.642	6.047	0.423	4.75e-12	NS
LUSC	Lung squamous cell carcinoma	51	501	5.511	6.34	0.819	2.86e-29	Over
OV	Ovarian serous cystadenocarcinoma	0	307	NA	6.639	NA	NA	NA
PAAD	Pancreatic adenocarcinoma	4	179	5.479	5.683	NA	NA	NA
PCPG	Pheochromocytoma and Paraganglioma	3	184	5.905	5.263	NA	NA	NA
PRAD	Prostate adenocarcinoma	52	498	5.734	5.83	0.098	0.0742	NS
READ	Rectum adenocarcinoma	10	167	6.056	6.067	0.079	0.6	NS
SARC	Sarcoma	2	263	5.227	5.677	NA	NA	NA
SKCM	Skin Cutaneous Melanoma	1	472	5.648	5.533	NA	NA	NA
STAD	Stomach adenocarcinoma	35	415	6.153	6.33	0.17	0.0102	NS
TGCT	Testicular Germ Cell Tumors	0	156	NA	6.438	NA	NA	NA
THCA	Thyroid carcinoma	59	509	6.144	6.278	0.132	0.00132	NS
THYM	Thymoma	2	120	6.094	6.201	NA	NA	NA
UCEC	Uterine Corpus Endometrial Carcinoma	35	546	5.724	6.04	0.312	0.000254	NS

> Cancer Cell Line Encyclopedia (CCLE)

[ TOP ]

Tissue	Cell Line	Expression Level (Microarray)
Autonomic ganglia	CHP126	11.8
Autonomic ganglia	CHP212	11.6
Autonomic ganglia	IMR32	11.6
Autonomic ganglia	KELLY	11.1
Autonomic ganglia	KPNRTBM1	11.6
Autonomic ganglia	KPNSI9S	11.2
Autonomic ganglia	KPNYN	11.8
Autonomic ganglia	MHHNB11	11.5
Autonomic ganglia	NB1	11.4
Autonomic ganglia	NH6	11.4
Autonomic ganglia	SHSY5Y	11.6
Autonomic ganglia	SIMA	11.9
Autonomic ganglia	SKNAS	11.6
Autonomic ganglia	SKNBE2	11.8
Autonomic ganglia	SKNDZ	11.1
Autonomic ganglia	SKNFI	11
Autonomic ganglia	SKNSH	11.2
Biliary tract	HUCCT1	11.9
Biliary tract	HUH28	11.3
Biliary tract	SNU1079	10.8
Biliary tract	SNU1196	12.6
Biliary tract	SNU245	12
Biliary tract	SNU308	12.2
Biliary tract	SNU478	11.7
Bone	143B	12.4
Bone	A673	11.5
Bone	CADOES1	11.2
Bone	CAL78	11.4
Bone	G292CLONEA141B1	11.9
Bone	HOS	12.2
Bone	HS706T	11.3
Bone	HS737T	11.3
Bone	HS819T	11.2
Bone	HS821T	11.1
Bone	HS822T	11.1
Bone	HS863T	11.3
Bone	HS870T	11.4
Bone	HS888T	11.4
Bone	MG63	11.6
Bone	MHHES1	11.6
Bone	OUMS27	11.2
Bone	RDES	11.2
Bone	SJSA1	11.3
Bone	SKES1	11.3
Bone	SKNMC	12
Bone	SW1353	11.5
Bone	T173	11.1
Bone	TC71	11.7
Bone	U2OS	11.3
Breast	AU565	11.7
Breast	BT20	12
Breast	BT474	12.2
Breast	BT483	12.5
Breast	BT549	11.3
Breast	CAL120	11.6
Breast	CAL148	11.7
Breast	CAL51	12
Breast	CAL851	11.4
Breast	CAMA1	11.9
Breast	DU4475	11.5
Breast	EFM192A	12.1
Breast	EFM19	12.1
Breast	EVSAT	11.9
Breast	HCC1143	12
Breast	HCC1187	12
Breast	HCC1395	11.8
Breast	HCC1419	11.6
Breast	HCC1428	12.4
Breast	HCC1500	11.6
Breast	HCC1569	11.4
Breast	HCC1599	12
Breast	HCC1806	11.6
Breast	HCC1937	12.1
Breast	HCC1954	11.6
Breast	HCC202	11.8
Breast	HCC2157	11.8
Breast	HCC2218	11.8
Breast	HCC38	11.9
Breast	HCC70	12.1
Breast	HDQP1	11.5
Breast	HMC18	11.9
Breast	HS274T	11.2
Breast	HS281T	11.2
Breast	HS343T	11.3
Breast	HS578T	11.1
Breast	HS606T	11
Breast	HS739T	11.1
Breast	HS742T	10.9
Breast	JIMT1	11
Breast	KPL1	12.4
Breast	MCF7	12
Breast	MDAMB134VI	11.8
Breast	MDAMB157	11.8
Breast	MDAMB175VII	11.7
Breast	MDAMB231	11.6
Breast	MDAMB361	11.4
Breast	MDAMB415	11.5
Breast	MDAMB436	11.1
Breast	MDAMB453	12.1
Breast	MDAMB468	11.6
Breast	SKBR3	11.4
Breast	T47D	11.9
Breast	UACC812	11.6
Breast	UACC893	11.1
Breast	YMB1	11.5
Breast	ZR751	11.9
Breast	ZR7530	12.1
Central nervous system	1321N1	11.3
Central nervous system	42MGBA	11.7
Central nervous system	8MGBA	11.7
Central nervous system	A172	11
Central nervous system	AM38	11.7
Central nervous system	BECKER	11.4
Central nervous system	CAS1	11.4
Central nervous system	CCFSTTG1	11.8
Central nervous system	D283MED	11.9
Central nervous system	D341MED	11.6
Central nervous system	DAOY	11.9
Central nervous system	DBTRG05MG	11
Central nervous system	DKMG	11.5
Central nervous system	GAMG	10.9
Central nervous system	GB1	11.6
Central nervous system	GI1	11.8
Central nervous system	GMS10	12
Central nervous system	GOS3	10.8
Central nervous system	H4	11.3
Central nervous system	HS683	11.4
Central nervous system	KALS1	11.6
Central nervous system	KG1C	10.5
Central nervous system	KNS42	11.2
Central nervous system	KNS60	11.4
Central nervous system	KNS81	10.6
Central nervous system	KS1	11.4
Central nervous system	LN18	11.6
Central nervous system	LN229	11.2
Central nervous system	M059K	11.9
Central nervous system	MOGGCCM	11.4
Central nervous system	MOGGUVW	11.2
Central nervous system	NMCG1	11.3
Central nervous system	ONS76	11.3
Central nervous system	SF126	11.5
Central nervous system	SF295	11.6
Central nervous system	SNB19	11.2
Central nervous system	SNU1105	11.3
Central nervous system	SNU201	10.9
Central nervous system	SNU466	11.1
Central nervous system	SNU489	11.2
Central nervous system	SNU626	11.1
Central nervous system	SNU738	11.6
Central nervous system	SW1088	11.3
Central nervous system	SW1783	11.4
Central nervous system	T98G	11.3
Central nervous system	TM31	11.6
Central nervous system	U118MG	11.3
Central nervous system	U138MG	10.9
Central nervous system	U251MG	10.8
Central nervous system	U87MG	11.5
Central nervous system	YH13	11.3
Central nervous system	YKG1	11.1
Endometrium	AN3CA	11.2
Endometrium	COLO684	12
Endometrium	EFE184	12
Endometrium	EN	12
Endometrium	ESS1	11.3
Endometrium	HEC108	11.6
Endometrium	HEC151	11.6
Endometrium	HEC1A	11.9
Endometrium	HEC1B	11.9
Endometrium	HEC251	10.8
Endometrium	HEC265	11.5
Endometrium	HEC50B	11.6
Endometrium	HEC59	11.5
Endometrium	HEC6	11.5
Endometrium	ISHIKAWAHERAKLIO02ER	11.8
Endometrium	JHUEM1	11.6
Endometrium	JHUEM2	11.6
Endometrium	JHUEM3	11.7
Endometrium	KLE	11.8
Endometrium	MFE280	12.1
Endometrium	MFE296	11.7
Endometrium	MFE319	11.9
Endometrium	RL952	11.9
Endometrium	SNGM	11.6
Endometrium	SNU1077	12
Endometrium	SNU685	11.4
Endometrium	TEN	11.9
Haematopoietic and lymphoid	697	12.2
Haematopoietic and lymphoid	A3KAW	11.6
Haematopoietic and lymphoid	A4FUK	11.8
Haematopoietic and lymphoid	ALLSIL	12.3
Haematopoietic and lymphoid	AML193	12
Haematopoietic and lymphoid	AMO1	11.8
Haematopoietic and lymphoid	BCP1	11.6
Haematopoietic and lymphoid	BDCM	11.9
Haematopoietic and lymphoid	BL41	12.3
Haematopoietic and lymphoid	BL70	12.4
Haematopoietic and lymphoid	BV173	11.9
Haematopoietic and lymphoid	CA46	12
Haematopoietic and lymphoid	CI1	12
Haematopoietic and lymphoid	CMK115	11.8
Haematopoietic and lymphoid	CMK86	12.1
Haematopoietic and lymphoid	CMK	11.8
Haematopoietic and lymphoid	CMLT1	12
Haematopoietic and lymphoid	COLO775	11.5
Haematopoietic and lymphoid	DAUDI	11.9
Haematopoietic and lymphoid	DB	11.8
Haematopoietic and lymphoid	DEL	12
Haematopoietic and lymphoid	DND41	12
Haematopoietic and lymphoid	DOHH2	12.2
Haematopoietic and lymphoid	EB1	12.1
Haematopoietic and lymphoid	EB2	12
Haematopoietic and lymphoid	EHEB	11.6
Haematopoietic and lymphoid	EJM	12.6
Haematopoietic and lymphoid	EM2	11.8
Haematopoietic and lymphoid	EOL1	11.9
Haematopoietic and lymphoid	F36P	12.1
Haematopoietic and lymphoid	GA10	12.4
Haematopoietic and lymphoid	GDM1	11.9
Haematopoietic and lymphoid	GRANTA519	11.6
Haematopoietic and lymphoid	HDLM2	11.6
Haematopoietic and lymphoid	HDMYZ	11.1
Haematopoietic and lymphoid	HEL9217	11.6
Haematopoietic and lymphoid	HEL	11.8
Haematopoietic and lymphoid	HH	11.9
Haematopoietic and lymphoid	HL60	12
Haematopoietic and lymphoid	HPBALL	12.2
Haematopoietic and lymphoid	HS604T	11.3
Haematopoietic and lymphoid	HS611T	11.9
Haematopoietic and lymphoid	HS616T	11.2
Haematopoietic and lymphoid	HS751T	11.4
Haematopoietic and lymphoid	HT	12
Haematopoietic and lymphoid	HTK	12.1
Haematopoietic and lymphoid	HUNS1	11.8
Haematopoietic and lymphoid	HUT102	11.7
Haematopoietic and lymphoid	HUT78	12
Haematopoietic and lymphoid	JEKO1	12
Haematopoietic and lymphoid	JK1	11.8
Haematopoietic and lymphoid	JM1	11.9
Haematopoietic and lymphoid	JURKAT	12.1
Haematopoietic and lymphoid	JURLMK1	12
Haematopoietic and lymphoid	JVM2	11.8
Haematopoietic and lymphoid	JVM3	12
Haematopoietic and lymphoid	K562	11.3
Haematopoietic and lymphoid	KARPAS299	11.9
Haematopoietic and lymphoid	KARPAS422	12.5
Haematopoietic and lymphoid	KARPAS620	12.4
Haematopoietic and lymphoid	KASUMI1	12
Haematopoietic and lymphoid	KASUMI2	12
Haematopoietic and lymphoid	KASUMI6	11.9
Haematopoietic and lymphoid	KCL22	11.9
Haematopoietic and lymphoid	KE37	12.1
Haematopoietic and lymphoid	KE97	11.8
Haematopoietic and lymphoid	KG1	12.2
Haematopoietic and lymphoid	KHM1B	11.5
Haematopoietic and lymphoid	KIJK	11.9
Haematopoietic and lymphoid	KMH2	12.3
Haematopoietic and lymphoid	KMM1	12.1
Haematopoietic and lymphoid	KMS11	12.1
Haematopoietic and lymphoid	KMS12BM	12.4
Haematopoietic and lymphoid	KMS18	12
Haematopoietic and lymphoid	KMS20	12.2
Haematopoietic and lymphoid	KMS21BM	11.2
Haematopoietic and lymphoid	KMS26	11.9
Haematopoietic and lymphoid	KMS27	11.7
Haematopoietic and lymphoid	KMS28BM	11.9
Haematopoietic and lymphoid	KMS34	11.4
Haematopoietic and lymphoid	KO52	12
Haematopoietic and lymphoid	KOPN8	11.8
Haematopoietic and lymphoid	KU812	12.5
Haematopoietic and lymphoid	KYO1	11.7
Haematopoietic and lymphoid	L1236	11.8
Haematopoietic and lymphoid	L363	11.6
Haematopoietic and lymphoid	L428	11.7
Haematopoietic and lymphoid	L540	12.2
Haematopoietic and lymphoid	LAMA84	11.8
Haematopoietic and lymphoid	LOUCY	12.4
Haematopoietic and lymphoid	LP1	11.8
Haematopoietic and lymphoid	M07E	12.4
Haematopoietic and lymphoid	MC116	12.2
Haematopoietic and lymphoid	ME1	11.9
Haematopoietic and lymphoid	MEC1	12.2
Haematopoietic and lymphoid	MEC2	12.3
Haematopoietic and lymphoid	MEG01	12.5
Haematopoietic and lymphoid	MHHCALL2	12.3
Haematopoietic and lymphoid	MHHCALL3	12.1
Haematopoietic and lymphoid	MHHCALL4	12.3
Haematopoietic and lymphoid	MINO	11.9
Haematopoietic and lymphoid	MJ	11.8
Haematopoietic and lymphoid	MM1S	11
Haematopoietic and lymphoid	MOLM13	11.8
Haematopoietic and lymphoid	MOLM16	12.4
Haematopoietic and lymphoid	MOLM6	11.6
Haematopoietic and lymphoid	MOLP2	11.8
Haematopoietic and lymphoid	MOLP8	11.6
Haematopoietic and lymphoid	MOLT13	12.1
Haematopoietic and lymphoid	MOLT16	12.2
Haematopoietic and lymphoid	MOLT4	11.9
Haematopoietic and lymphoid	MONOMAC1	11.8
Haematopoietic and lymphoid	MONOMAC6	12
Haematopoietic and lymphoid	MOTN1	11.3
Haematopoietic and lymphoid	MUTZ5	12.2
Haematopoietic and lymphoid	MV411	12.1
Haematopoietic and lymphoid	NALM19	11.9
Haematopoietic and lymphoid	NALM1	12.2
Haematopoietic and lymphoid	NALM6	12
Haematopoietic and lymphoid	NAMALWA	12.2
Haematopoietic and lymphoid	NB4	12
Haematopoietic and lymphoid	NCIH929	11.4
Haematopoietic and lymphoid	NCO2	12
Haematopoietic and lymphoid	NOMO1	12.2
Haematopoietic and lymphoid	NUDHL1	11.5
Haematopoietic and lymphoid	NUDUL1	12.3
Haematopoietic and lymphoid	OCIAML2	11.8
Haematopoietic and lymphoid	OCIAML3	11.9
Haematopoietic and lymphoid	OCIAML5	11.8
Haematopoietic and lymphoid	OCILY10	12.7
Haematopoietic and lymphoid	OCILY19	12
Haematopoietic and lymphoid	OCILY3	11.9
Haematopoietic and lymphoid	OCIM1	11.7
Haematopoietic and lymphoid	OPM2	12.1
Haematopoietic and lymphoid	P12ICHIKAWA	12.1
Haematopoietic and lymphoid	P31FUJ	11.8
Haematopoietic and lymphoid	P3HR1	12.1
Haematopoietic and lymphoid	PCM6	11.7
Haematopoietic and lymphoid	PEER	12.8
Haematopoietic and lymphoid	PF382	11.9
Haematopoietic and lymphoid	PFEIFFER	12.3
Haematopoietic and lymphoid	PL21	11.6
Haematopoietic and lymphoid	RAJI	11.9
Haematopoietic and lymphoid	RCHACV	12.1
Haematopoietic and lymphoid	REC1	12.2
Haematopoietic and lymphoid	REH	12.1
Haematopoietic and lymphoid	RI1	11.9
Haematopoietic and lymphoid	RL	11.8
Haematopoietic and lymphoid	RPMI8226	11.3
Haematopoietic and lymphoid	RPMI8402	12.2
Haematopoietic and lymphoid	RS411	12.2
Haematopoietic and lymphoid	SEM	11.9
Haematopoietic and lymphoid	SET2	12.2
Haematopoietic and lymphoid	SIGM5	12
Haematopoietic and lymphoid	SKM1	12.2
Haematopoietic and lymphoid	SKMM2	11.6
Haematopoietic and lymphoid	SR786	11.8
Haematopoietic and lymphoid	ST486	12.5
Haematopoietic and lymphoid	SUDHL10	11.4
Haematopoietic and lymphoid	SUDHL1	11.9
Haematopoietic and lymphoid	SUDHL4	11.7
Haematopoietic and lymphoid	SUDHL5	12.6
Haematopoietic and lymphoid	SUDHL6	12.6
Haematopoietic and lymphoid	SUDHL8	12
Haematopoietic and lymphoid	SUPB15	12
Haematopoietic and lymphoid	SUPHD1	12
Haematopoietic and lymphoid	SUPM2	11.5
Haematopoietic and lymphoid	SUPT11	12.4
Haematopoietic and lymphoid	SUPT1	12.2
Haematopoietic and lymphoid	TALL1	12.4
Haematopoietic and lymphoid	TF1	12.3
Haematopoietic and lymphoid	THP1	11.9
Haematopoietic and lymphoid	TO175T	11.4
Haematopoietic and lymphoid	TOLEDO	12.4
Haematopoietic and lymphoid	U266B1	11.7
Haematopoietic and lymphoid	U937	11.8
Haematopoietic and lymphoid	UT7	11.5
Haematopoietic and lymphoid	WSUDLCL2	11.9
Kidney	769P	11.2
Kidney	786O	11
Kidney	A498	10.9
Kidney	A704	10.7
Kidney	ACHN	11.2
Kidney	BFTC909	11.4
Kidney	CAKI1	11
Kidney	CAKI2	11.5
Kidney	CAL54	11.3
Kidney	KMRC1	10.9
Kidney	KMRC20	11.1
Kidney	KMRC2	11.1
Kidney	KMRC3	11.4
Kidney	OSRC2	11.1
Kidney	RCC10RGB	10.9
Kidney	SNU1272	11.1
Kidney	SNU349	11.1
Kidney	TUHR10TKB	11.2
Kidney	TUHR14TKB	11
Kidney	TUHR4TKB	10.7
Kidney	VMRCRCW	10.8
Kidney	VMRCRCZ	11.2
Large intestine	C2BBE1	11.5
Large intestine	CCK81	12
Large intestine	CL11	11.9
Large intestine	CL14	11.4
Large intestine	CL34	11.6
Large intestine	CL40	11.3
Large intestine	COLO205	11.7
Large intestine	COLO320	11.6
Large intestine	COLO678	11.6
Large intestine	CW2	12
Large intestine	DLD1	11.9
Large intestine	GP2D	12
Large intestine	HCC56	11.6
Large intestine	HCT116	11.9
Large intestine	HCT15	12.1
Large intestine	HS675T	11.1
Large intestine	HS698T	11
Large intestine	HT115	11.9
Large intestine	HT29	11.7
Large intestine	HT55	12.1
Large intestine	KM12	11.8
Large intestine	LOVO	12
Large intestine	LS1034	11.6
Large intestine	LS123	11.7
Large intestine	LS180	11.5
Large intestine	LS411N	11.8
Large intestine	LS513	11.8
Large intestine	MDST8	11.3
Large intestine	NCIH508	11.2
Large intestine	NCIH716	12.1
Large intestine	NCIH747	11.3
Large intestine	OUMS23	12
Large intestine	RCM1	12.1
Large intestine	RKO	11.3
Large intestine	SKCO1	12.1
Large intestine	SNU1040	11.9
Large intestine	SNU1197	11.7
Large intestine	SNU175	11.8
Large intestine	SNU283	11.7
Large intestine	SNU407	11.6
Large intestine	SNU503	12.3
Large intestine	SNU61	12.2
Large intestine	SNU81	12.3
Large intestine	SNUC1	11.8
Large intestine	SNUC2A	11.6
Large intestine	SNUC4	11.6
Large intestine	SNUC5	11.7
Large intestine	SW1116	11.8
Large intestine	SW1417	11.7
Large intestine	SW1463	12
Large intestine	SW403	11.5
Large intestine	SW480	11.6
Large intestine	SW48	12.1
Large intestine	SW620	11.8
Large intestine	SW837	12.3
Large intestine	SW948	11.6
Large intestine	T84	12
Liver	ALEXANDERCELLS	11.1
Liver	C3A	11.5
Liver	HEP3B217	11.7
Liver	HEPG2	11.2
Liver	HLE	11.2
Liver	HLF	11.5
Liver	HUH1	11.3
Liver	HUH6	12
Liver	HUH7	11.3
Liver	JHH1	11.9
Liver	JHH2	10.9
Liver	JHH4	11.9
Liver	JHH5	11.9
Liver	JHH6	11.7
Liver	JHH7	11.3
Liver	LI7	11.4
Liver	PLCPRF5	11.3
Liver	SKHEP1	11.6
Liver	SNU182	11.8
Liver	SNU387	11.4
Liver	SNU398	12.3
Liver	SNU423	11.1
Liver	SNU449	11.5
Liver	SNU475	11.8
Liver	SNU761	11.3
Liver	SNU878	11.3
Liver	SNU886	11.5
Lung	A549	11.7
Lung	ABC1	11.8
Lung	BEN	11.4
Lung	CAL12T	12.2
Lung	CALU1	11.8
Lung	CALU3	11.9
Lung	CALU6	12
Lung	CHAGOK1	12.4
Lung	COLO668	12.2
Lung	COLO699	11.2
Lung	CORL105	11.9
Lung	CORL23	12.2
Lung	CORL24	12.1
Lung	CORL279	11.8
Lung	CORL311	11.9
Lung	CORL47	12.4
Lung	CORL51	12.2
Lung	CORL88	12
Lung	CORL95	11.8
Lung	CPCN	11.8
Lung	DMS114	11.6
Lung	DMS153	11.1
Lung	DMS273	12
Lung	DMS454	12.2
Lung	DMS53	10.9
Lung	DMS79	12.2
Lung	DV90	11.3
Lung	EBC1	12
Lung	EPLC272H	11.4
Lung	HARA	12
Lung	HCC1171	12.1
Lung	HCC1195	11.7
Lung	HCC15	11.7
Lung	HCC2279	11.8
Lung	HCC2935	12.2
Lung	HCC33	12.1
Lung	HCC366	11.8
Lung	HCC4006	12.4
Lung	HCC44	11.8
Lung	HCC78	11.6
Lung	HCC827	12
Lung	HCC95	11.9
Lung	HLC1	11.7
Lung	HLFA	11.2
Lung	HS229T	11.4
Lung	HS618T	11.2
Lung	IALM	11.9
Lung	KNS62	11.7
Lung	LC1F	12.2
Lung	LC1SQSF	12.3
Lung	LCLC103H	11.6
Lung	LCLC97TM1	12.2
Lung	LK2	11.4
Lung	LOUNH91	10.8
Lung	LU65	11.5
Lung	LU99	11.6
Lung	LUDLU1	12
Lung	LXF289	11.8
Lung	MORCPR	12
Lung	NCIH1048	12
Lung	NCIH1092	12.1
Lung	NCIH1105	12.1
Lung	NCIH1155	11.5
Lung	NCIH1184	12
Lung	NCIH1299	12.2
Lung	NCIH1339	12
Lung	NCIH1341	11.6
Lung	NCIH1355	11.8
Lung	NCIH1373	12.1
Lung	NCIH1385	11.1
Lung	NCIH1395	11
Lung	NCIH1435	11.5
Lung	NCIH1436	12.1
Lung	NCIH1437	12.3
Lung	NCIH146	11.1
Lung	NCIH1563	11.9
Lung	NCIH1568	11.9
Lung	NCIH1573	11.7
Lung	NCIH1581	12.4
Lung	NCIH1618	12
Lung	NCIH1623	12.1
Lung	NCIH1648	11.8
Lung	NCIH1650	12
Lung	NCIH1651	11.5
Lung	NCIH1666	11.5
Lung	NCIH1693	11.6
Lung	NCIH1694	12.5
Lung	NCIH1703	11.6
Lung	NCIH1734	12.1
Lung	NCIH1755	11.7
Lung	NCIH1781	12.6
Lung	NCIH1792	11.7
Lung	NCIH1793	11.7
Lung	NCIH1836	12.1
Lung	NCIH1838	11.3
Lung	NCIH1869	11.9
Lung	NCIH1876	12.1
Lung	NCIH1915	11.6
Lung	NCIH1930	12
Lung	NCIH1944	11.5
Lung	NCIH1963	12
Lung	NCIH196	12
Lung	NCIH1975	12.1
Lung	NCIH2009	12
Lung	NCIH2023	11.7
Lung	NCIH2029	11.3
Lung	NCIH2030	11.8
Lung	NCIH2066	11.9
Lung	NCIH2081	12.2
Lung	NCIH2085	11.7
Lung	NCIH2087	11.6
Lung	NCIH209	11.8
Lung	NCIH2106	10.7
Lung	NCIH2110	12
Lung	NCIH211	11.5
Lung	NCIH2122	11.5
Lung	NCIH2126	11.7
Lung	NCIH2141	12.3
Lung	NCIH2170	11.8
Lung	NCIH2171	11.8
Lung	NCIH2172	12.7
Lung	NCIH2196	11.1
Lung	NCIH2227	11.8
Lung	NCIH2228	12.1
Lung	NCIH226	11.3
Lung	NCIH2286	12.3
Lung	NCIH2291	11.5
Lung	NCIH2342	12.3
Lung	NCIH2347	12.2
Lung	NCIH23	11.7
Lung	NCIH2405	12
Lung	NCIH2444	11.7
Lung	NCIH292	11.3
Lung	NCIH322	11.8
Lung	NCIH3255	12.2
Lung	NCIH358	12.4
Lung	NCIH441	11.6
Lung	NCIH446	11.9
Lung	NCIH460	11.8
Lung	NCIH510	12
Lung	NCIH520	11.6
Lung	NCIH522	11.9
Lung	NCIH524	12.2
Lung	NCIH526	12
Lung	NCIH596	12.1
Lung	NCIH647	11.7
Lung	NCIH650	12.1
Lung	NCIH661	11.5
Lung	NCIH69	12
Lung	NCIH727	11.8
Lung	NCIH810	11.8
Lung	NCIH82	11.6
Lung	NCIH838	12.2
Lung	NCIH841	11.8
Lung	NCIH854	11.9
Lung	NCIH889	11.5
Lung	PC14	10.7
Lung	RERFLCAD1	11.4
Lung	RERFLCAD2	11.7
Lung	RERFLCAI	11.7
Lung	RERFLCKJ	11.7
Lung	RERFLCMS	11.6
Lung	RERFLCSQ1	11.5
Lung	SBC5	11.4
Lung	SCLC21H	12.2
Lung	SHP77	11.7
Lung	SKLU1	11.8
Lung	SKMES1	11.4
Lung	SQ1	12.1
Lung	SW1271	11.9
Lung	SW1573	11.6
Lung	SW900	11.6
Lung	VMRCLCD	11.9
Lung	VMRCLCP	12.3
Oesophagus	COLO680N	12.1
Oesophagus	ECGI10	11.8
Oesophagus	KYSE140	12.1
Oesophagus	KYSE150	11.9
Oesophagus	KYSE180	12.4
Oesophagus	KYSE270	12.3
Oesophagus	KYSE30	11.6
Oesophagus	KYSE410	12.1
Oesophagus	KYSE450	11.6
Oesophagus	KYSE510	12.2
Oesophagus	KYSE520	12.1
Oesophagus	KYSE70	11.7
Oesophagus	OE19	11.9
Oesophagus	OE33	11.9
Oesophagus	TE10	12.6
Oesophagus	TE11	12.2
Oesophagus	TE14	12.1
Oesophagus	TE15	12
Oesophagus	TE1	11.5
Oesophagus	TE4	11.7
Oesophagus	TE5	11.7
Oesophagus	TE6	12.7
Oesophagus	TE8	12
Oesophagus	TE9	12
Oesophagus	TT	12.1
Ovary	59M	11.4
Ovary	A2780	11.9
Ovary	CAOV3	12
Ovary	CAOV4	11.4
Ovary	COLO704	11.9
Ovary	COV318	12.2
Ovary	COV362	12.4
Ovary	COV434	11.9
Ovary	COV504	11.2
Ovary	COV644	11.9
Ovary	EFO21	12.2
Ovary	EFO27	11.2
Ovary	ES2	11.4
Ovary	FUOV1	12.3
Ovary	HEYA8	11.6
Ovary	HS571T	10.9
Ovary	IGROV1	11.7
Ovary	JHOC5	11.4
Ovary	JHOM1	12.1
Ovary	JHOM2B	12.1
Ovary	JHOS2	12
Ovary	JHOS4	11.9
Ovary	KURAMOCHI	11.6
Ovary	MCAS	11.8
Ovary	NIHOVCAR3	12.1
Ovary	OAW28	12.8
Ovary	OAW42	11.8
Ovary	OC314	12
Ovary	OC316	11.9
Ovary	ONCODG1	11.7
Ovary	OV56	12
Ovary	OV7	11.8
Ovary	OV90	11.9
Ovary	OVCAR4	11.9
Ovary	OVCAR8	11.9
Ovary	OVISE	11.7
Ovary	OVK18	11.4
Ovary	OVKATE	12
Ovary	OVMANA	11.4
Ovary	OVSAHO	11
Ovary	OVTOKO	11.8
Ovary	RMGI	11.8
Ovary	RMUGS	12
Ovary	SKOV3	12
Ovary	SNU119	11.7
Ovary	SNU840	12
Ovary	SNU8	11.8
Ovary	TOV112D	12.2
Ovary	TOV21G	11.8
Ovary	TYKNU	11.4
Pancreas	ASPC1	11.4
Pancreas	BXPC3	11.9
Pancreas	CAPAN1	12.2
Pancreas	CAPAN2	12.1
Pancreas	CFPAC1	12.1
Pancreas	DANG	11.5
Pancreas	HPAC	11.9
Pancreas	HPAFII	12.2
Pancreas	HS766T	11.1
Pancreas	HUPT3	11.9
Pancreas	HUPT4	11.8
Pancreas	KCIMOH1	11.8
Pancreas	KLM1	12.2
Pancreas	KP2	11.2
Pancreas	KP3	11.5
Pancreas	KP4	11.7
Pancreas	L33	12.1
Pancreas	MIAPACA2	12
Pancreas	PANC0203	12.2
Pancreas	PANC0213	11.4
Pancreas	PANC0327	11.7
Pancreas	PANC0403	11.7
Pancreas	PANC0504	12
Pancreas	PANC0813	11.8
Pancreas	PANC1005	11.5
Pancreas	PANC1	11.5
Pancreas	PATU8902	11.8
Pancreas	PATU8988S	12.3
Pancreas	PATU8988T	11.9
Pancreas	PK1	12
Pancreas	PK45H	11.4
Pancreas	PK59	11.9
Pancreas	PL45	11.6
Pancreas	PSN1	11.9
Pancreas	QGP1	11.2
Pancreas	SNU213	12
Pancreas	SNU324	11.6
Pancreas	SNU410	11.3
Pancreas	SU8686	11.5
Pancreas	SUIT2	11.9
Pancreas	SW1990	12
Pancreas	T3M4	11.7
Pancreas	TCCPAN2	12.3
Pancreas	YAPC	12.2
Pleura	ACCMESO1	11.1
Pleura	DM3	10.8
Pleura	ISTMES1	12
Pleura	ISTMES2	11.9
Pleura	JL1	10.8
Pleura	MPP89	11.7
Pleura	MSTO211H	11.4
Pleura	NCIH2052	11.3
Pleura	NCIH2452	11.2
Pleura	NCIH28	11.1
Prostate	22RV1	11.6
Prostate	DU145	12
Prostate	LNCAPCLONEFGC	11.4
Prostate	MDAPCA2B	11.3
Prostate	NCIH660	12.4
Prostate	PC3	11.6
Prostate	VCAP	11.8
Salivary gland	A253	11.9
Salivary gland	YD15	11.8
Skin	A101D	11.2
Skin	A2058	11.5
Skin	A375	11.5
Skin	C32	10.9
Skin	CHL1	11.5
Skin	CJM	12.3
Skin	COLO679	10.8
Skin	COLO741	10.7
Skin	COLO783	11.2
Skin	COLO792	11.4
Skin	COLO800	11.3
Skin	COLO818	11
Skin	COLO829	11.4
Skin	COLO849	11.9
Skin	G361	11.3
Skin	GRM	11.7
Skin	HMCB	11.6
Skin	HS294T	11.2
Skin	HS600T	11.2
Skin	HS688AT	11.3
Skin	HS695T	10.9
Skin	HS839T	11.4
Skin	HS852T	11.7
Skin	HS895T	10.8
Skin	HS934T	11.3
Skin	HS936T	10.9
Skin	HS939T	11.3
Skin	HS940T	11.1
Skin	HS944T	11.3
Skin	HT144	11.6
Skin	IGR1	11.6
Skin	IGR37	11.1
Skin	IGR39	11.3
Skin	IPC298	11.1
Skin	K029AX	10.7
Skin	LOXIMVI	12
Skin	MALME3M	11.1
Skin	MDAMB435S	11.1
Skin	MELHO	11.4
Skin	MELJUSO	10.7
Skin	MEWO	11.8
Skin	RPMI7951	11.7
Skin	RVH421	11
Skin	SH4	11.1
Skin	SKMEL1	10
Skin	SKMEL24	11.5
Skin	SKMEL28	11
Skin	SKMEL2	11.2
Skin	SKMEL30	11.5
Skin	SKMEL31	10.7
Skin	SKMEL3	10.8
Skin	SKMEL5	11.4
Skin	UACC257	11.3
Skin	UACC62	11.6
Skin	WM115	11.3
Skin	WM1799	11.3
Skin	WM2664	11.4
Skin	WM793	11.2
Skin	WM88	11.3
Skin	WM983B	11.6
Small intestine	HUTU80	12
Soft tissue	A204	11.6
Soft tissue	G401	11.7
Soft tissue	G402	11.5
Soft tissue	GCT	11.5
Soft tissue	HS729	11.7
Soft tissue	HT1080	11.4
Soft tissue	KYM1	12.1
Soft tissue	MESSA	11.8
Soft tissue	RD	11.6
Soft tissue	RH30	11.9
Soft tissue	RH41	12
Soft tissue	RKN	11.3
Soft tissue	S117	11.7
Soft tissue	SJRH30	11.9
Soft tissue	SKLMS1	11.7
Soft tissue	SKUT1	12
Soft tissue	TE125T	11
Soft tissue	TE159T	11.1
Soft tissue	TE441T	11.9
Soft tissue	TE617T	11.6
Stomach	2313287	12
Stomach	AGS	12.1
Stomach	AZ521	11.7
Stomach	ECC10	11.9
Stomach	ECC12	12.1
Stomach	FU97	11.2
Stomach	GCIY	11.7
Stomach	GSS	11.8
Stomach	GSU	12.3
Stomach	HGC27	12
Stomach	HS746T	11.7
Stomach	HUG1N	11.8
Stomach	IM95	12
Stomach	KATOIII	11.5
Stomach	KE39	12
Stomach	LMSU	11.9
Stomach	MKN1	12
Stomach	MKN45	12
Stomach	MKN74	11.9
Stomach	MKN7	11.5
Stomach	NCCSTCK140	11.9
Stomach	NCIN87	11.6
Stomach	NUGC2	11.8
Stomach	NUGC3	11.3
Stomach	NUGC4	11.6
Stomach	OCUM1	12.1
Stomach	RERFGC1B	12.2
Stomach	SH10TC	11.9
Stomach	SNU16	12
Stomach	SNU1	11.8
Stomach	SNU216	12.3
Stomach	SNU520	11
Stomach	SNU5	11.2
Stomach	SNU601	11.3
Stomach	SNU620	12
Stomach	SNU668	11.2
Stomach	SNU719	12.1
Stomach	TGBC11TKB	11.3
Thyroid	8305C	11.5
Thyroid	8505C	11.7
Thyroid	BCPAP	11.9
Thyroid	BHT101	11.8
Thyroid	CAL62	11
Thyroid	CGTHW1	11.7
Thyroid	FTC133	11.6
Thyroid	FTC238	11.6
Thyroid	ML1	11.4
Thyroid	SW579	11.7
Thyroid	TT2609C02	12
Thyroid	TT	11.1
Upper aerodigestive tract	BHY	11.4
Upper aerodigestive tract	BICR16	12.2
Upper aerodigestive tract	BICR18	11.4
Upper aerodigestive tract	BICR22	11.9
Upper aerodigestive tract	BICR31	11.9
Upper aerodigestive tract	BICR56	11.7
Upper aerodigestive tract	BICR6	11.7
Upper aerodigestive tract	CAL27	11.6
Upper aerodigestive tract	CAL33	11.4
Upper aerodigestive tract	DETROIT562	11.9
Upper aerodigestive tract	FADU	11.9
Upper aerodigestive tract	HS840T	11.4
Upper aerodigestive tract	HSC2	11.6
Upper aerodigestive tract	HSC3	11.7
Upper aerodigestive tract	HSC4	11.8
Upper aerodigestive tract	PECAPJ15	11.8
Upper aerodigestive tract	PECAPJ34CLONEC12	12.3
Upper aerodigestive tract	PECAPJ41CLONED2	11.4
Upper aerodigestive tract	PECAPJ49	11.8
Upper aerodigestive tract	SCC15	11.5
Upper aerodigestive tract	SCC25	12
Upper aerodigestive tract	SCC4	12.3
Upper aerodigestive tract	SCC9	11.3
Upper aerodigestive tract	SNU1076	12
Upper aerodigestive tract	SNU1214	11.9
Upper aerodigestive tract	SNU46	11.8
Upper aerodigestive tract	SNU899	11.2
Upper aerodigestive tract	YD10B	11.6
Upper aerodigestive tract	YD38	11.4
Upper aerodigestive tract	YD8	12
Urinary tract	5637	11.5
Urinary tract	639V	11.7
Urinary tract	647V	11.9
Urinary tract	BC3C	12
Urinary tract	BFTC905	12.1
Urinary tract	CAL29	11.6
Urinary tract	HS172T	11
Urinary tract	HT1197	12
Urinary tract	HT1376	11.6
Urinary tract	J82	11.6
Urinary tract	JMSU1	12.1
Urinary tract	KMBC2	12.4
Urinary tract	KU1919	12.3
Urinary tract	RT11284	11.9
Urinary tract	RT112	11.8
Urinary tract	RT4	11.9
Urinary tract	SCABER	11.6
Urinary tract	SW1710	11
Urinary tract	SW780	11.9
Urinary tract	T24	11.5
Urinary tract	TCCSUP	10.5
Urinary tract	UMUC1	11.9
Urinary tract	UMUC3	11.4
Urinary tract	VMCUB1	11.3

> The Human Protein Atlas (HPA)

[ TOP ]

Tissue	Expression Level (TPM)
Adipose tissue	31.8
Adrenal gland	36.7
Appendix	43
Bone marrow	37.7
Breast	34
Cerebral cortex	37.6
Cervix, uterine	38.8
Colon	32.5
Duodenum	31.2
Endometrium	43.9
Epididymis	43.4
Esophagus	34.5
Fallopian tube	38.4
Gallbladder	38
Heart muscle	17
Kidney	36.7
Liver	25.2
Lung	37.5
Lymph node	44.7
Ovary	28.9
Pancreas	5.5
Parathyroid gland	55.1
Placenta	51.6
Prostate	41.9
Rectum	34.7
Salivary gland	11.6
Seminal vesicle	33.6
Skeletal muscle	11.5
Skin	35.2
Small intestine	35.5
Smooth muscle	38.9
Spleen	45.5
Stomach	25.8
Testis	49.2
Thyroid gland	65.8
Tonsil	39.4
Urinary bladder	38.7

> Text Mining based Expression

[ TOP ]

PMID	Expression	Cancer	Evidence
28485541	Overexpression	Laryngeal Carcinoma	YY1 and MYCT1 were upregulated and downregulated at transcriptional level in laryngeal cancer, respectively, which showed a negative correlation between YY1 and MYCT1 expression in laryngeal cancer.
28394354	Overexpression	Lung Carcinoma	Clinical evidence further confirms that high expression of MCT-1 is associated with an increase in YY1, EGFR and MnSOD expression, accompanied by tumor recurrence, poor overall survival and EGFR mutation status in patients with lung cancers.
27829535	Overexpression	Rheumatoid Arthritis	In this study, we found that YY1 was over-expressed in RA patients and CIA mice.
27793842	Overexpression	Pancreatic Carcinoma	Here, we show how KRAS acts through inflammatory NF-κB signaling to activate the transcription factor YY1, which represses expression of the tumor suppressor gene miR-489.
27663660	Overexpression	Colon Carcinoma	In summary, our investigation revealed that miR-215 was downregulated in colon cancer and it suppressed colon cancer cell proliferation, migration and invasion by directly targeting YY1.
27086928	Overexpression	Colon Carcinoma	WNT signaling microarray, immunoblotting and immunohistochemistry analyses of tumors derived from the Villin-Cre;Nedd4(fl/fl);Apc(+/min) colons demonstrated elevated expression of the WNT upstream effectors LEF1 (full length) and YY1 in these tumors relative to control (Apc(+/min) alone) tumors.
27312530	Overexpression	Bladder Carcinoma; Lung Carcinoma; Prostate Carcinoma	In clinical bladder cancer specimens, expression of GON4L, YY1, and CD24 was elevated compared with normal bladder urothelium. This pathway is biologically relevant in other cancer types as well, where CD24 and the androgen receptor are clinically prognostic, given that silencing of GON4L and YY1 suppressed CD24 expression and growth of human lung, prostate, and breast cancer cells.
27225481	Overexpression	Skin Carcinoma; Testis Cancer; Breast Carcinoma; Colorectal Carcinoma; Lymphoma; Melanoma	The relationship between YY1 and SOX2 expressions as well as the expressions of BMI1 and OCT4 resulted in the classification of four groups of cancers with distinct molecular signatures: (1) Prostate, lung, cervical, endometrial, ovarian and glioma cancers (YY1(lo)SOX2(hi)BMI1(hi)OCT4(hi)) (2) Skin, testis and breast cancers (YY1(hi)SOX2(lo)BMI1(hi)OCT4(hi)) (3) Liver, stomach, renal, pancreatic and urothelial cancers (YY1(lo)SOX2(lo)BMI1(hi)OCT4(hi)) and (4) Colorectal cancer, lymphoma and melanoma (YY1(hi)SOX2(hi)BMI1(lo)OCT4(hi)).
27225481	Underexpression	Prostate Carcinoma; Lung Carcinoma; Endometrial Carcinoma; Ovarian Carcinoma; Glioma Carcinoma; Hepatocellular Carcinoma; Gastric Carcinoma; Urothelial Carcinoma	The relationship between YY1 and SOX2 expressions as well as the expressions of BMI1 and OCT4 resulted in the classification of four groups of cancers with distinct molecular signatures: (1) Prostate, lung, cervical, endometrial, ovarian and glioma cancers (YY1(lo)SOX2(hi)BMI1(hi)OCT4(hi)) (2) Skin, testis and breast cancers (YY1(hi)SOX2(lo)BMI1(hi)OCT4(hi)) (3) Liver, stomach, renal, pancreatic and urothelial cancers (YY1(lo)SOX2(lo)BMI1(hi)OCT4(hi)) and (4) Colorectal cancer, lymphoma and melanoma (YY1(hi)SOX2(hi)BMI1(lo)OCT4(hi)).
27087319	Overexpression	Pancreatic Insulinoma	Positive expression for YY1 protein was detected in both benign and malignant tumor tissues, but the malignant tissues had a significantly greater intensity of YY1 expression than the benign tissues (P=0.042). The intensity of YY1 expression was positively correlated with the nature of the tumor, and the insulinomas with high expressions of YY1 had significantly greater malignant potentials (P=0.037).
26800240	Overexpression	HBV-associated Hepatocellular Carcinoma	Gene expression analysis of human HBV-associated HCC specimens demonstrated concordant overexpression of YY1 and EZH2, which correlated with poor survival of patients in advanced stages.
26104682	Overexpression	Melanoma	Elevated YY1 levels were observed in patients with melanoma, compared with benign nevi and normal tissue controls, and the increased YY1 was associated with melanoma metastasis state and tumor stage.
25698133	Overexpression	Thyroid Gland Papillary Carcinoma; Thyroid Gland Follicular Carcinoma	YY1 was overexpressed in thyroid cancer cells, at transcription and protein levels. A significant increase of YY1 mRNA was also observed in tumor thyroid tissues. Moreover, immunohistochemical analysis of the thyroid cancer tissue microarray revealed that both papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) present increased YY1 protein levels (48 and 19%, respectively).
25328408	Overexpression	Esophageal Squamous Cell Carcinoma	However, the YY1 protein level was significantly higher in ESCC tissues with lymph node metastasis than those without lymph node metastasis (P=0.042). Furthermore, the expression of the YY1 protein was stronger in stage III-IV patients than in stage I-II patients (P=0.002), but the protein levels between different histological grades (well, moderate, or poor) showed no statistical significance.
25174820	Overexpression	Prostate Carcinoma	By contrast, YY1 expression was elevated in PCa tumors as compared with that in PIN, and was increased with higher tumor grade.
25053986	Overexpression	Prostate Carcinoma	YY1 expression is upregulated in human prostate cancer cell lines and tissues.
24970600	Overexpression	Plasma Cell Myeloma	Significantly, higher expression (staining intensity and cell frequency) of YY1 in MM cell lines and in bone marrow-derived (BM) MM from 22 MM patients was observed as compared to expression in normal BM. Higher nuclear YY1 staining was associated with disease progression. Bioinformatic analyses of mRNA in data sets corroborated the above findings and showed significant overexpression of YY1 in MM compared to normal tissues and other hematopoietic disorders.
24884523	Overexpression	Pancreatic Ductal Adenocarcinoma	We found that the expression of YY1 in PDACs was higher compared with their adjacent non-tumorous tissues and normal pancreas tissues.
24674326	Overexpression	Gastric Carcinoma	YY1 expression was up-regulated in gastric cancer cell lines and primary gastric cancers
24481728	Overexpression	Renal Cell Carcinoma	In the present study, we demonstrated that levels of YY1 were significantly increased in primary RCC tissues when compared to these levels in the matched healthy tissues.
24481661	Overexpression	Plasma Cell Myeloma	Computational analysis of various GEO datasets revealed elevated YY1 and RKIP levels in MM vs. the normal plasma cells, as well as elevated RKIP levels in MM vs. normal B lymphocytes
23919806	Overexpression	Esophageal Squamous Cell Carcinoma	We found that the expression of YY1 mRNA was significantly increased in the tumor tissues, compared with the para-tissues or normal esophageal tissues.
23874387	Overexpression	Plasma Cell Myeloma	Here, we report that Yin Yang1 (YY1), a target gene for NF-κB, is hyperexpressed in most MM tumor cells obtained from human patients, exhibits constitutive nuclear localization, and is essential for survival of MM cells
23705901	Overexpression	Kidney Angiomyolipomas	YY1 was also significantly increased in tumor tissue of AMLs compared to control kidney tissue suggesting that YY1 plays a major role in the regulation of αSMA
23328582	Overexpression	Colorectal Carcinoma	Furthermore, multivariate analysis revealed that patients with YY1 protein high expression had a significant decrease in overall survival, and Kaplan-Meier survival curves showed that these patients had significantly shorter survival than others (P<0.0001).
22907428	Overexpression	Endometrioid Endometrial Carcinoma	We demonstrated that YY1 is upregulated in EEC cell lines and primary tumors; and its expression is associated with tumor stages.
22536409	Overexpression	Prostatic Intraepithelial Neoplasia	Increased YY1 levels are observed in prostatic intraepithelial neoplasia (PIN) and advanced disease.
22440256	Overexpression	Breast Carcinoma	We observed that, compared with normal samples, YY1 is generally overexpressed in breast cancer cells and tissues.
22391813	Overexpression	Hepatocellular Carcinoma	We found that YY1 was upregulated in HCC cell lines.
22162832	Overexpression	Osteosarcoma	Overexpression of YY1 in primary site of osteosarcoma is associated with the occurrence of metastasis and poor clinical outcome.
21735472	Overexpression	Cervical Carcinoma	These results demonstrated that the expression of YY1 is upregulated in cervical carcinomas and that YY1 plays a critical role in the progression of HPV-positive cervical cancer.
21503900	Overexpression	hepatoblastoma	Eight genes, including YY1 and IGF1, were upregulated in HBL cases that had a poor prognosis.
21332389	Overexpression	Hepatocellular Carcinoma	Hyperactivation of YY1 in tumors was corroborated by its nuclear localization and the finding that in the tumors there were also increases in YY1AP, a YY1 coactivator not expressed in normal liver, and in survivin, as a possible target of YY1.
21109702	Overexpression	Follicular Lymphoma	Quantification of YY1 protein was carried out on 26 FL biopsy samples using quantum dot labelled immunohistochemistry. Ki-67 percentage, grade, YY1 protein levels and T cell and macrophage markers were used in a multivariable analysis for survival in 26 cases of FL. Expression levels of YY1 protein were significantly increased in patients alive in comparison with those dead after follow-up (p ≤ 0.025).
20081364	Overexpression	Lymphoma	In the present study, using computational methods, we showed that YY1 transcript levels were significantly increased in the high-grade lymphomas, including Burkitt's lymphoma and diffuse large B-cell lymphoma (DLBCL), compared with those of both low-grade lymphomas and normal B-cells.
20025767	Overexpression	Breast Carcinoma	AP-2alpha/beta significantly correlated with YY1 and both markers were increased in luminal oestrogen receptor (ER) positive tumours of small size and low grade but only AP-2alpha/beta correlated with good prognosis breast cancer specific survival and disease free interval (BCSS and DFI).
19668226	Overexpression	Prostate Carcinoma	YY1 is highly expressed in various types of cancers, including prostate cancer.
19360355	Overexpression	Colon Carcinoma	In this study, we report that YY1 was uniformly highly over-expressed in a wide range of human cancer cell lines and in human colon cancer tissue samples.
18488713	Overexpression	Osteosarcoma	These results indicate that overexpression of YY1 in osteosarcoma cells plays a key role in positive regulation of RIZ1.
17549406	Overexpression	Cervical intraepithelial neoplasia; Cervical Carcinoma	VEGF and TGF-beta1 mRNA overexpression was found to be associated with progression from low-grade to high-grade cervical intraepithelial neoplasia (CIN), while YY1 showed constitutively elevated transcript levels in CIN and cervical cancer compared to controls.
16962318	Overexpression	Osteosarcoma	By using Western blot analysis, we have shown that the YY1 protein is strongly expressed in human osteosarcoma cells and localised mainly in the nucleus.
15942652	Overexpression	Prostate Carcinoma	This study used tissue microarrays to investigate the expression and localization of YY1 in 1364 representative tissue samples from 246 hormone naive prostate cancer patients who underwent radical prostatectomy. Staining intensity and frequency measures for both YY1 nuclear and cytoplasmic expression were higher in neoplastic tissues and in PIN samples compared to matched benign cells (p < 0.0001 for all comparisons)
12393438	Overexpression	Acute Myeloid Leukemia	Increased YY1 expression was seen in some cases of human AML.

Summary
Symbol	YY1
Name	YY1 transcription factor
Aliases	UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Location	14q32.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Somatic copy number alteration in primary tomur tissue

> The Cancer Genome Atlas (TCGA)

[ TOP ]

Correlation between expression and SCNA as well as percentage of patients in different status.

Cancer	Full Name	# Sample	R	P	% Loss	% Neutral	% Gain	Status
BLCA	Bladder urothelial carcinoma	404	0.517	5.15e-29	29.2	52.7	18.1	Neutral
BRCA	Breast invasive carcinoma	1075	0.503	4.89e-70	28.5	56.4	15.2	Neutral
CESC	Cervical and endocervical cancers	292	0.617	4.53e-32	16.8	66.8	16.4	Neutral
COAD	Colon adenocarcinoma	449	0.554	1.99e-37	33	59.9	7.1	Neutral
ESCA	Esophageal carcinoma	183	0.543	2.1e-15	30.6	42.1	27.3	Neutral
GBM	Glioblastoma multiforme	147	0.577	1.92e-14	33.3	60.5	6.1	Neutral
HNSC	Head and Neck squamous cell carcinoma	514	0.586	1.22e-48	13.2	54.5	32.3	Neutral
KIRC	Kidney renal clear cell carcinoma	525	0.487	1.16e-32	43	54.1	2.9	Loss
KIRP	Kidney renal papillary cell carcinoma	288	0.192	0.00104	17.7	81.6	0.7	Neutral
LAML	Acute Myeloid Leukemia	166	0.142	0.0674	0	98.8	1.2	Neutral
LGG	Brain Lower Grade Glioma	513	0.476	2.16e-30	20.9	78.4	0.8	Neutral
LIHC	Liver hepatocellular carcinoma	364	0.51	1.54e-25	36	58.5	5.5	Loss
LUAD	Lung adenocarcinoma	512	0.478	1.3e-30	27.9	48.4	23.6	Neutral
LUSC	Lung squamous cell carcinoma	498	0.69	1.27e-71	31.3	37.1	31.5	Neutral
OV	Ovarian serous cystadenocarcinoma	300	0.736	2.08e-52	37.7	41	21.3	Loss
PAAD	Pancreatic adenocarcinoma	177	0.266	0.000338	10.7	74	15.3	Neutral
PCPG	Pheochromocytoma and Paraganglioma	162	0.536	1.98e-13	14.8	81.5	3.7	Neutral
PRAD	Prostate adenocarcinoma	491	0.294	3.02e-11	7.7	88.6	3.7	Neutral
READ	Rectum adenocarcinoma	164	0.637	4.45e-20	42.1	51.2	6.7	Loss
SARC	Sarcoma	255	0.568	3.25e-23	25.1	49.4	25.5	Neutral
SKCM	Skin Cutaneous Melanoma	367	0.409	3.04e-16	31.6	56.1	12.3	Neutral
STAD	Stomach adenocarcinoma	413	0.434	2.08e-20	29.5	60.3	10.2	Neutral
TGCT	Testicular Germ Cell Tumors	150	0.256	0.00154	15.3	48.7	36	Gain
THCA	Thyroid carcinoma	497	0.147	0.000975	0.2	97.4	2.4	Neutral
THYM	Thymoma	119	0.095	0.307	1.7	87.4	10.9	Neutral
UCEC	Uterine Corpus Endometrial Carcinoma	537	0.375	2.15e-19	10.4	78.6	11	Neutral

Summary
Symbol	YY1
Name	YY1 transcription factor
Aliases	UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Location	14q32.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Methylation level in the promoter region of CR

> Methylation level in the promoter region of CR

[ TOP ]

Correlation between expression and methylation as well as differential methylation analysis.

Cancer	Full Name	R	P	# N	# T	Delta beta (T vs N)	P value (T vs N)	Status
BLCA	Bladder urothelial carcinoma	-0.128	0.00843	17	408	-0.004	0.0711	NS/NA
BRCA	Breast invasive carcinoma	-0.326	0	83	785	0.002	1.15e-12	NS/NA
CESC	Cervical and endocervical cancers	-0.189	0.00085	3	306	NA	NA	NS/NA
COAD	Colon adenocarcinoma	-0.243	1.3e-05	19	297	0.001	0.0163	NS/NA
ESCA	Esophageal carcinoma	-0.294	3.43e-05	9	185	NA	NA	NS/NA
GBM	Glioblastoma multiforme	-0.341	0.00573	1	64	NA	NA	NS/NA
HNSC	Head and Neck squamous cell carcinoma	-0.236	2.93e-08	20	522	0.002	3.9e-06	NS/NA
KIRC	Kidney renal clear cell carcinoma	-0.196	0.000259	24	319	0.003	8.58e-08	NS/NA
KIRP	Kidney renal papillary cell carcinoma	-0.298	1.8e-07	23	275	0.004	1.72e-09	NS/NA
LAML	Acute Myeloid Leukemia	-0.087	0.259	0	170	NA	NA	NS/NA
LGG	Brain Lower Grade Glioma	-0.157	0.000289	0	530	NA	NA	NS/NA
LIHC	Liver hepatocellular carcinoma	-0.272	2.21e-08	41	373	0	0.000674	NS/NA
LUAD	Lung adenocarcinoma	-0.077	0.0918	21	456	-0.001	0.611	NS/NA
LUSC	Lung squamous cell carcinoma	-0.296	4.96e-09	8	370	NA	NA	NS/NA
OV	Ovarian serous cystadenocarcinoma	-0.667	0.0589	0	9	NA	NA	NS/NA
PAAD	Pancreatic adenocarcinoma	-0.015	0.844	4	179	NA	NA	NS/NA
PCPG	Pheochromocytoma and Paraganglioma	-0.245	0.000732	3	184	NA	NA	NS/NA
PRAD	Prostate adenocarcinoma	-0.082	0.0571	35	498	0.001	1.16e-05	NS/NA
READ	Rectum adenocarcinoma	-0.183	0.0666	2	99	NA	NA	NS/NA
SARC	Sarcoma	-0.23	0.000176	0	263	NA	NA	NS/NA
SKCM	Skin Cutaneous Melanoma	-0.313	4.57e-12	1	471	NA	NA	NS/NA
STAD	Stomach adenocarcinoma	-0.107	0.0384	0	372	NA	NA	NS/NA
TGCT	Testicular Germ Cell Tumors	-0.106	0.188	0	156	NA	NA	NS/NA
THCA	Thyroid carcinoma	-0.146	0.000553	50	509	-0.001	0.677	NS/NA
THYM	Thymoma	-0.11	0.228	2	120	NA	NA	NS/NA
UCEC	Uterine Corpus Endometrial Carcinoma	-0.126	0.00642	34	431	-0.001	0.0783	NS/NA

Summary
Symbol	YY1
Name	YY1 transcription factor
Aliases	UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Location	14q32.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Primary tumor tissue from TCGA > Normal tumor tissue from HPA

>The Cancer Genome Atlas (TCGA) [ TOP ]
There is no record.

> The Human Protein Atlas (HPA)

[ TOP ]

Tissue	Level	Level Name
Adrenal gland	2	Medium
Appendix	2	Medium
Bone marrow	2	Medium
Breast	1	Low
Bronchus	2	Medium
Caudate	1	Low
Cerebellum	1	Low
Cerebral cortex	1	Low
Cervix, uterine	2	Medium
Colon	2	Medium
Duodenum	2	Medium
Endometrium	2	Medium
Epididymis	2	Medium
Esophagus	2	Medium
Fallopian tube	2	Medium
Gallbladder	2	Medium
Heart muscle	1	Low
Hippocampus	1	Low
Kidney	2	Medium
Liver	1	Low
Lung	2	Medium
Lymph node	2	Medium
Nasopharynx	2	Medium
Oral mucosa	2	Medium
Ovary	3	High
Pancreas	2	Medium
Parathyroid gland	2	Medium
Placenta	3	High
Prostate	1	Low
Rectum	2	Medium
Salivary gland	2	Medium
Seminal vesicle	2	Medium
Skeletal muscle	1	Low
Skin	2	Medium
Small intestine	2	Medium
Smooth muscle	1	Low
Soft tissue	2	Medium
Spleen	2	Medium
Stomach	2	Medium
Testis	2	Medium
Thyroid gland	2	Medium
Tonsil	2	Medium
Urinary bladder	3	High
Vagina	2	Medium

Summary
Symbol	YY1
Name	YY1 transcription factor
Aliases	UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Location	14q32.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Association between expresson and subtype > Overall survival analysis based on expression > Association between expresson and stage > Association between expresson and grade

> Subtype

[ TOP ]

Association between expresson and subtype.

Cancer	Full Name	# Patients	P Value (Kruskal-Wallis)	Association	Source
BLCA	Bladder urothelial carcinoma	128	0.239	NS	24476821
BRCA	Breast invasive carcinoma	521	0.00721	Significant	23000897
COAD	Colon adenocarcinoma	149	0.00161	Significant	22810696
GBM	Glioblastoma multiforme	157	0.0171	Significant	26824661
HNSC	Head and Neck squamous cell carcinoma	279	0.000153	Significant	25631445
KIRP	Kidney renal papillary cell carcinoma	161	8.81e-06	Significant	26536169
LGG	Brain Lower Grade Glioma	513	0.21	NS	26824661
LUAD	Lung adenocarcinoma	230	1.02e-07	Significant	25079552
LUSC	Lung squamous cell carcinoma	178	0.000429	Significant	22960745
OV	Ovarian serous cystadenocarcinoma	287	0.364	NS	21720365
PRAD	Prostate adenocarcinoma	333	0.133	NS	26544944
READ	Rectum adenocarcinoma	67	0.799	NS	22810696
SKCM	Skin Cutaneous Melanoma	315	0.00508	Significant	26091043
STAD	Stomach adenocarcinoma	277	1.68e-05	Significant	25079317
THCA	Thyroid carcinoma	391	0.308	NS	25417114
UCEC	Uterine Corpus Endometrial Carcinoma	232	4.04e-09	Significant	23636398

> Overall survival

[ TOP ]

Overall survival analysis based on expression.

Cancer	Full Name	# Patients	Hazard Ratio	P Value (Log Rank Test)	Association
BLCA	Bladder urothelial carcinoma	405	1.241	0.309	NS
BRCA	Breast invasive carcinoma	1079	0.975	0.91	NS
CESC	Cervical and endocervical cancers	291	1.038	0.91	NS
COAD	Colon adenocarcinoma	439	0.744	0.335	NS
ESCA	Esophageal carcinoma	184	0.902	0.755	NS
GBM	Glioblastoma multiforme	158	0.724	0.2	NS
HNSC	Head and Neck squamous cell carcinoma	518	1.289	0.201	NS
KIRC	Kidney renal clear cell carcinoma	531	0.527	0.00233	Longer
KIRP	Kidney renal papillary cell carcinoma	287	3.414	0.00569	Shorter
LAML	Acute Myeloid Leukemia	149	0.864	0.631	NS
LGG	Brain Lower Grade Glioma	511	0.891	0.633	NS
LIHC	Liver hepatocellular carcinoma	365	1.45	0.121	NS
LUAD	Lung adenocarcinoma	502	1.97	0.004	Shorter
LUSC	Lung squamous cell carcinoma	494	0.646	0.0287	Longer
OV	Ovarian serous cystadenocarcinoma	303	0.835	0.404	NS
PAAD	Pancreatic adenocarcinoma	177	2.724	0.000462	Shorter
PCPG	Pheochromocytoma and Paraganglioma	179	1651368850.719	0.0433	Shorter
PRAD	Prostate adenocarcinoma	497	3.173	0.162	NS
READ	Rectum adenocarcinoma	159	3.144	0.076	NS
SARC	Sarcoma	259	1.22	0.513	NS
SKCM	Skin Cutaneous Melanoma	459	0.954	0.809	NS
STAD	Stomach adenocarcinoma	388	0.898	0.63	NS
TGCT	Testicular Germ Cell Tumors	134	0	0.335	NS
THCA	Thyroid carcinoma	500	0.642	0.506	NS
THYM	Thymoma	119	0.169	0.11	NS
UCEC	Uterine Corpus Endometrial Carcinoma	543	1.78	0.0581	NS

> Stage

[ TOP ]

Association between expresson and stage.

Cancer	Full Name	# Patients	R Value (Spearman)	P Value (Spearman)	Association
BLCA	Bladder urothelial carcinoma	406	-0.062	0.216	NS
BRCA	Breast invasive carcinoma	1071	-0.036	0.24	NS
CESC	Cervical and endocervical cancers	167	-0.06	0.442	NS
COAD	Colon adenocarcinoma	445	-0.078	0.102	NS
ESCA	Esophageal carcinoma	162	-0.062	0.436	NS
HNSC	Head and Neck squamous cell carcinoma	448	0.069	0.146	NS
KIRC	Kidney renal clear cell carcinoma	531	-0.08	0.0647	NS
KIRP	Kidney renal papillary cell carcinoma	260	0.301	7.28e-07	Higher
LIHC	Liver hepatocellular carcinoma	347	0.056	0.298	NS
LUAD	Lung adenocarcinoma	507	0.05	0.26	NS
LUSC	Lung squamous cell carcinoma	497	0.163	0.000266	Higher
OV	Ovarian serous cystadenocarcinoma	302	-0.075	0.194	NS
PAAD	Pancreatic adenocarcinoma	176	0.211	0.00504	Higher
READ	Rectum adenocarcinoma	156	0.012	0.879	NS
SKCM	Skin Cutaneous Melanoma	410	-0.051	0.302	NS
STAD	Stomach adenocarcinoma	392	0.007	0.894	NS
TGCT	Testicular Germ Cell Tumors	81	-0.147	0.189	NS
THCA	Thyroid carcinoma	499	0.011	0.805	NS
UCEC	Uterine Corpus Endometrial Carcinoma	501	0.176	7.5e-05	Higher

> Grade

[ TOP ]

Association between expresson and grade.

Cancer	Full Name	# Patients	R Value (Spearman)	P Value (Spearman)	Association
CESC	Cervical and endocervical cancers	272	0.048	0.435	NS
HNSC	Head and Neck squamous cell carcinoma	498	-0.081	0.0702	NS
KIRC	Kidney renal clear cell carcinoma	525	-0.137	0.00165	Lower
LGG	Brain Lower Grade Glioma	514	0.07	0.113	NS
LIHC	Liver hepatocellular carcinoma	366	-0.106	0.0421	Lower
OV	Ovarian serous cystadenocarcinoma	296	0.023	0.689	NS
PAAD	Pancreatic adenocarcinoma	176	0.135	0.0731	NS
STAD	Stomach adenocarcinoma	406	-0.125	0.0119	Lower
UCEC	Uterine Corpus Endometrial Carcinoma	534	0.344	2.87e-16	Higher

Summary
Symbol	YY1
Name	YY1 transcription factor
Aliases	UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Location	14q32.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Targets inferred by reverse engineering method > Targets identified by ChIP-seq data

> Targets inferred by reverse engineering method [ TOP ]

> Targets identified by ChIP-seq data [ TOP ]

Summary
Symbol	YY1
Name	YY1 transcription factor
Aliases	UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Location	14q32.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Drugs from DrugBank database

> Drugs from DrugBank database [ TOP ]
There is no record for YY1.

Summary
Symbol	YY1
Name	YY1 transcription factor
Aliases	UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Location	14q32.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Protein-Protein Interaction Network > miRNA Regulatory Relationship > Interactions from Text Mining

> Protein-Protein Interaction Network [ TOP ]

> miRNA Regulatory Relationship [ TOP ]

> Interactions from Text Mining

[ TOP ]

PMID	Cancer	Hierarchy	Gene	Relation to CR	Evidence
28505004	Plasma Cell Myeloma	partner	EWSR1	Fusion	A gene fusion involving EWSR1 and YY1 gene on 14q32 has been reported in 2 patients over the age of 60 with peritoneal MM.
28485541	Laryngeal Carcinoma	partner	MYCT1	Negative correlation	YY1 and MYCT1 were upregulated and downregulated at transcriptional level in laryngeal cancer, respectively, which showed a negative correlation between YY1 and MYCT1 expression in laryngeal cancer.
27829535	Rheumatoid Arthritis	downstream	IL-6	Positive regulation	Finally, we showed YY1 positively regulated IL-6 transcription by binding to the promoter region of the IL-6 gene.
27793842	Pancreatic Carcinoma	upstream	KRAS	Positive regulation	Here, we show how KRAS acts through inflammatory NF-κB signaling to activate the transcription factor YY1, which represses expression of the tumor suppressor gene miR-489.
27663660	Colon Carcinoma	upstream	miR-215	Negative regulation	In summary, our investigation revealed that miR-215 was downregulated in colon cancer and it suppressed colon cancer cell proliferation, migration and invasion by directly targeting YY1.
27086928	Colon Carcinoma	downstream	WNT	Positive regulation	WNT signaling microarray, immunoblotting and immunohistochemistry analyses of tumors derived from the Villin-Cre;Nedd4(fl/fl);Apc(+/min) colons demonstrated elevated expression of the WNT upstream effectors LEF1 (full length) and YY1 in these tumors relative to control (Apc(+/min) alone) tumors.
27312530	Bladder Carcinoma; Lung Carcinoma; Prostate Carcinoma	partner	GON4L	binding	Mechanistically, GON4L interacted with transcription factor YY1, promoting its association with the androgen receptor to drive CD24 expression and cell growth.
27312530	Bladder Carcinoma; Lung Carcinoma; Prostate Carcinoma	downstream	CD24	Positive regulation	This pathway is biologically relevant in other cancer types as well, where CD24 and the androgen receptor are clinically prognostic, given that silencing of GON4L and YY1 suppressed CD24 expression and growth of human lung, prostate, and breast cancer cells.
26800240	HBV-associated Hepatocellular Carcinoma	partner	EZH2	Positive correlation	Gene expression analysis of human HBV-associated HCC specimens demonstrated concordant overexpression of YY1 and EZH2, which correlated with poor survival of patients in advanced stages.
26800240	HBV-associated Hepatocellular Carcinoma	downstream	NF-κB signalling	Positive regulation	In conclusion, YY1 overexpression contributes to EZH2 recruitment for H3K27me3-mediated silencing of tumour-suppressive microRNAs, thereby activating NF-κB signalling in hepatocarcinogenesis
26104682	Melanoma	downstream	miR-9	Negative regulation	Furthermore, YY1 negatively regulated miR-9 transcription. Silencing of YY1 inhibited proliferation, cell cycle progression, migration and invasion in melanoma cells, while ectopic of miR-9 did the same. Additionally, RYBP was shown to be a direct target of miR-9 through binding to its 3' UTR, thus forming a YY1~miR-9~RYBP axis.
25787250	Pancreatic Insulinoma	downstream	cAMP and Ca(2+) signaling pathways	Positive regulation	These findings indicate that YY1(T372R) mutations are neomorphic, resulting in constitutive activation of cAMP and Ca(2+) signaling pathways involved in insulin secretion.
25174820	Prostate Carcinoma	downstream	DR5	negative regulation	Death receptor5 (DR5) has been implicated in the prognosis of several cancers and it has been previously shown that it is negatively regulated by Yin Yang1 (YY1) in prostate cancer cell lines.
24884523	Pancreatic Ductal Adenocarcinoma	partner	MMP10	Negative correlation	YY1 expression levels were statistically negatively correlated with MMP10 expression levels, but not correlated with MUC4 expression levels
24674326	Gastric Carcinoma	downstream	Wnt/β-catenin pathway	Positive regulation	Knocking down YY1 in gastric cancer cells suppressed proliferation by inhibiting Wnt/β-catenin pathway, whereas its overexpression exerted oncogenic property by activating Wnt/β-catenin pathway.
24481728	Renal Cell Carcinoma	upstream	miR-34a	Negative regulation	Since YY1 is a direct target of miR-34a, the low level of miR-34a increased the expression of YY1, promoting the aggressiveness of RCC cells. 24481728-10 YY1 The expression of miR-34a displayed an inverse correlation with YY1, but a positive correlation with C/EBPα.
24481728	Renal Cell Carcinoma	downstream	C/EBPα; miR-34a.	Negative regulation	We observed that overexpression of YY1 caused repression of C/EBPα and the inhibition of C/EBPα led to the suppression of miR-34a.
23919806	Esophageal Squamous Cell Carcinoma	downstream	HO-1	Positive regulation	Moreover, besides P21, heme oxygenase-1 (HO-1) was identified as a YY1 downstream effector, as YY1 stimulated HO-1 expression in esophageal cancer cells.
23874387	Plasma Cell Myeloma	partner	RelA	form complex	Mechanistically, we report a novel YY1-RelA complex formation, which is essential to transcriptionally repress a proapoptotic gene Bim.
23874387	Plasma Cell Myeloma	downstream	Bim	Negative regulation	Mechanistically, we report a novel YY1-RelA complex formation, which is essential to transcriptionally repress a proapoptotic gene Bim.
23630070	Mesothelioma	partner	EWSR1	Fusion	Screening 15 additional cases of mesothelioma from which we had RNA but no cytogenetic information, we identified one more tumor carrying an EWSR1-YY1 fusion gene but not the reciprocal YY1-EWSR1 transcript
23328582	Colorectal Carcinoma	upstream	miR-7	Negative regulation	In conclusion, MiR-7 is a novel miRNA with tumor suppressive function in colon cancer by targeting oncogenic YY1.
23328582	Colorectal Carcinoma	downstream	p53; Wnt signaling pathways	negative regulation; positive regulation	YY1 promotes colon cancer growth through inhibiting p53 and promoting Wnt signaling pathways and serves as an independent prognostic biomarker for CRC patients.
22907428	Endometrioid Endometrial Carcinoma	upstream	miR-193a-5p	Negative regulation	Moreover, YY1 overexpression was found to be a consequence of miR-193a-5p downregulation through direct miR-193a-5p-YY1 interplay.
22907428	Endometrioid Endometrial Carcinoma	partner	EZH2	Recruitment	Further mechanistic investigation uncovered a new epigenetic silencing mode of APC by YY1 through recruitment of EZH2 and trimethylation of histone 3 lysine 27 on its promoter region.
22907428	Endometrioid Endometrial Carcinoma	downstream	APC	Negative regulation	Transcriptome analysis revealed a significant effect of YY1 on critical aspects of EEC tumorigenesis through inhibition of APC expression
22440256	Breast Carcinoma	downstream	p27	Negative regulation	Furthermore, we detected an inverse correlation between YY1 and p27 expression in both breast cancer cells and xenograft tumors with manipulated YY1 expression. Counteracting the changes in p27 expression attenuated the effects of YY1 alterations on these cells. In addition, YY1 promoted p27 ubiquitination and physically interacted with p27.
22391813	Hepatocellular Carcinoma	downstream	CEBPA	negative regulation	CCAAT/enhancer-binding protein alpha (CEBPA) which was important to regulate differentiation of hepatocytes was found as the direct target downregulated by YY1.
21735472	Cervical Carcinoma	upstream	As2O3	regulation	Thus, YY1 is an As2O3 target and could serve as a potential drug sensitizer for anti-cervical cancer therapy.
21735472	Cervical Carcinoma	partner	HDAC1	binding	Furthermore, YY1 was physically associated with HDAC1 in a manner dependent on mTOR activation
21503900	hepatoblastoma	downstream	HBV-induced HLJ1	Positive regulation	Knockdown of YY1 expression could partially reduce the HBV-induced HLJ1 activation which indicated that YY1 would be involved in HBV-induced HLJ1 expression.
21332389	Hepatocellular Carcinoma	partner	YY1AP; RKIP	coactivator; negative correlation	Hyperactivation of YY1 in tumors was corroborated by its nuclear localization and the finding that in the tumors there were also increases in YY1AP, a YY1 coactivator not expressed in normal liver, and in survivin, as a possible target of YY1. The ratio of YY1 to RKIP mRNA was constantly profoundly inverted in the tumors compared with the adjacent nontumoral tissues.
20081364	Lymphoma	partner	BCL-6; PAX-5	Positive correlation	The association of YY1 expression with some clinical-pathological features in DLBCL showed a positive correlation between a high level of YY1 mRNA and high levels of BCL-6 protein. Moreover, by analyzing the large series of DLBCL in the Hummel dataset, we identified the transcription factor PAX-5 among the top 50 genes positively correlated with YY1.
20025767	Breast Carcinoma	partner	AP-2alpha/beta; HER2	Positive correlation; correlation	AP-2alpha/beta significantly correlated with YY1 and both markers were increased in luminal oestrogen receptor (ER) positive tumours of small size and low grade but only AP-2alpha/beta correlated with good prognosis breast cancer specific survival and disease free interval (BCSS and DFI). AP-2alpha and YY1 showed a significant correlation with Her2 protein expression and in addition, YY1 correlated with HER2 gene expression.
19668226	Prostate Carcinoma	downstream	AR	Regulation	Consistently, YY1 depletion in LNCaP cells reduced endogenous PSA levels, but overexpressed YY1 did not significantly increase PSA expression. We also observed that YY1-AR interaction is essential to YY1-mediated transcription activity of AR and YY1 is a necessary component in the complex binding to the androgen response element. Thus, our study demonstrates that YY1 interacts with AR and regulates its transcriptional activity.
18488713	Osteosarcoma	downstream	RIZ1	Positive regulation	These results indicate that overexpression of YY1 in osteosarcoma cells plays a key role in positive regulation of RIZ1.
17549406	Cervical intraepithelial neoplasia; Cervical Carcinoma	partner	VEGF; TGF-beta1	Negative correlation	Spearman analysis revealed a co-expression pattern for VEGF and TGF-beta1 mRNAs in normal cervix and LG-SIL; however, YY1 expression correlated negatively with VEGF and TGF-beta1 transcript levels upon the onset of the cervical neoplastic transformation.